| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Victor Navarro | |
| Naemat Sandhu | |||
| P2860 | cites work | A study of western pharmaceuticals contained within samples of Chinese herbal/patent medicines collected from New York City's Chinatown | Q80671765 |
| Drug-induced Liver Injury | Q84847182 | ||
| High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury | Q85758004 | ||
| Mortality associated with drug-induced liver injury (DILI) | Q89928808 | ||
| Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group | Q90426654 | ||
| Incidence and Etiology of Drug-Induced Liver Injury in Mainland China | Q91454956 | ||
| Hepatotoxicity of immune check point inhibitors: Approach and management | Q91806394 | ||
| Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods | Q92403226 | ||
| Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019 | Q92510476 | ||
| EASL Clinical Practice Guidelines: Drug-induced liver injury | Q92705067 | ||
| Drug-induced liver injury: a clinical update | Q24617074 | ||
| Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure | Q24635175 | ||
| The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative | Q26764776 | ||
| RUCAM in Drug and Herb Induced Liver Injury: The Update | Q26771817 | ||
| Local control of the immune response in the liver | Q28144211 | ||
| Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury | Q28237500 | ||
| Idiosyncratic drug reactions: past, present, and future | Q28259484 | ||
| Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry | Q28276237 | ||
| Isoniazid-associated hepatitis in 114 patients | Q28338980 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Drug-induced liver injury: recent advances in diagnosis and risk assessment | Q30235089 | ||
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination | Q30251438 | ||
| Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. | Q30949867 | ||
| Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data | Q31171172 | ||
| Liver injury from herbal and dietary supplements | Q33887186 | ||
| Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes | Q33894632 | ||
| Content versus label claims in ephedra-containing dietary supplements | Q33903706 | ||
| Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury | Q33917967 | ||
| Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States | Q34165115 | ||
| Hepatotoxicity of antibiotics. | Q34289694 | ||
| Drug-induced liver disorders: implications for drug development and regulation | Q34303460 | ||
| Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period | Q34440712 | ||
| Dietary supplement use in the United States, 2003-2006 | Q34493137 | ||
| Anabolic androgenic steroid-induced hepatotoxicity. | Q34532752 | ||
| Hepatotoxicity associated with dietary supplements containing anabolic steroids | Q34629365 | ||
| Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset | Q34848118 | ||
| Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. | Q34880762 | ||
| Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network | Q34943114 | ||
| Methimazole-induced hepatotoxicity | Q35017564 | ||
| Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles | Q35085772 | ||
| Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method | Q35644300 | ||
| Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study | Q35656015 | ||
| Acute and clinically relevant drug-induced liver injury: a population based case-control study. | Q35826210 | ||
| Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications | Q36479455 | ||
| Idiosyncratic drug reactions: current understanding | Q36551883 | ||
| Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct | Q36799781 | ||
| Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States | Q36844723 | ||
| Steroid use in acute liver failure | Q36939687 | ||
| Liver injury from nonsteroidal anti-inflammatory drugs in the United States | Q37280079 | ||
| A systems-pharmacology analysis of herbal medicines used in health improvement treatment: predicting potential new drugs and targets | Q37393093 | ||
| Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements | Q37399866 | ||
| Carnitine in the treatment of valproic acid-induced toxicity | Q37413086 | ||
| Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience | Q37613243 | ||
| Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations | Q37624916 | ||
| Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts | Q37662544 | ||
| Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes | Q37710785 | ||
| Drug-induced acute liver failure: results of a U.S. multicenter, prospective study | Q37711165 | ||
| Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver | Q37818983 | ||
| Case definition and phenotype standardization in drug-induced liver injury. | Q37872195 | ||
| Acetaminophen-related hepatotoxicity | Q38149899 | ||
| Drug-induced liver injury with autoimmune features | Q38216272 | ||
| Trends in Dietary Supplement Use Among US Adults From 1999-2012. | Q38405295 | ||
| Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians | Q38649906 | ||
| Drug-Induced Liver Disease: Clinical Course | Q39008371 | ||
| Drug-induced Liver Injury: The Hepatic Pathologist's Approach | Q39307576 | ||
| Effects of alcohol on other hepatotoxins | Q39588437 | ||
| Incidence of drug-induced hepatic injuries: a French population-based study | Q39609276 | ||
| Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States | Q39741682 | ||
| The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware | Q40181580 | ||
| Budd-Chiari syndrome associated with oral contraceptive steroids. Review of treatment of 47 cases | Q40273123 | ||
| Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements | Q40422372 | ||
| Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. | Q40454552 | ||
| Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries | Q40775438 | ||
| Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts | Q42548382 | ||
| Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis | Q42791977 | ||
| Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. | Q43050091 | ||
| The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury | Q43539187 | ||
| Differential effect of valproate and its Delta2- and Delta4-unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. | Q43744184 | ||
| Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists | Q43867427 | ||
| Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients w | Q44496896 | ||
| Cephalexin-induced cholestatic hepatitis | Q45057477 | ||
| Effect of Green Tea Supplements on Liver Enzyme Elevation: Results from a Randomized Intervention Study in the United States | Q46341218 | ||
| Cholestatic liver injury after glimepiride therapy | Q46483268 | ||
| Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals | Q46613608 | ||
| Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden | Q46705824 | ||
| Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. | Q46708383 | ||
| Dietary supplement use among infants, children, and adolescents in the United States, 1999-2002. | Q46972041 | ||
| Herbal and Dietary Supplement-induced Liver Injuries in the Spanish DILI Registry. | Q47200469 | ||
| Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting | Q47415795 | ||
| Histopathological challenges in suspected drug-induced liver injury | Q48136372 | ||
| Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. | Q50015039 | ||
| Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. | Q50848238 | ||
| Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. | Q51206003 | ||
| FATTY LIVER OF PREGNANCY AND ITS RELATIONSHIP TO TETRACYCLINE THERAPY. | Q51255176 | ||
| Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. | Q51635879 | ||
| The spectrum of hepatotoxicity. | Q52754925 | ||
| Hepatic Suppression of Sensitization to Antigen absorbed into the Portal System | Q59070387 | ||
| A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients | Q59509669 | ||
| Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period | Q60344407 | ||
| Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II | Q68164131 | ||
| The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury | Q71563600 | ||
| Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge | Q72576810 | ||
| Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis | Q73712041 | ||
| Amiodarone-induced disruption of hamster lung and liver mitochondrial function: lack of association with thiobarbituric acid-reactive substance production | Q77425816 | ||
| Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic | Q79171844 | ||
| Drug-induced liver injury at an Asian center: a prospective study | Q80085799 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 631-645 | |
| P577 | publication date | 2020-03-13 | |
| P1433 | published in | Hepatology Communications | Q50817751 |
| P1476 | title | Drug-Induced Liver Injury in GI Practice | |
| P478 | volume | 4 |
Search more.